• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

类药性密度:一种基于蛋白质数据库中大量口袋和类药性配体来量化蛋白质靶标“可结合性”的方法。

Drug-like density: a method of quantifying the "bindability" of a protein target based on a very large set of pockets and drug-like ligands from the Protein Data Bank.

机构信息

Chemistry Modeling and Informatics Department, Merck Research Laboratories, Rahway, New Jersey 07065, USA.

出版信息

J Chem Inf Model. 2010 Nov 22;50(11):2029-40. doi: 10.1021/ci100312t. Epub 2010 Oct 26.

DOI:10.1021/ci100312t
PMID:20977231
Abstract

One approach to estimating the "chemical tractability" of a candidate protein target where we know the atomic resolution structure is to examine the physical properties of potential binding sites. A number of other workers have addressed this issue. We characterize ~290,000 "pockets" from ~42,000 protein crystal structures in terms of a three parameter "pocket space": volume, buriedness, and hydrophobicity. A metric DLID (drug-like density) measures how likely a pocket is to bind a drug-like molecule. This is calculated from the count of other pockets in its local neighborhood in pocket space that contain drug-like cocrystallized ligands and the count of total pockets in the neighborhood. Surprisingly, despite being defined locally, a global trend in DLID can be predicted by a simple linear regression on log(volume), buriedness, and hydrophobicity. Two levels of simplification are necessary to relate the DLID of individual pockets to "targets": taking the best DLID per Protein Data Bank (PDB) entry (because any given crystal structure can have many pockets), and taking the median DLID over all PDB entries for the same target (because different crystal structures of the same protein can vary because of artifacts and real conformational changes). We can show that median DLIDs for targets that are detectably homologous in sequence are reasonably similar and that median DLIDs correlate with the "druggability" estimate of Cheng et al. (Nature Biotechnology 2007, 25, 71-75).

摘要

一种评估候选蛋白质靶标“化学可处理性”的方法是检查潜在结合位点的物理性质。许多其他研究人员已经解决了这个问题。我们根据三个参数“口袋空间”(体积、埋置度和疏水性)来描述来自约 42000 个蛋白质晶体结构的约 290000 个“口袋”。一种度量标准 DLID(药物样密度)用于衡量口袋与药物样分子结合的可能性。这是通过计算口袋空间中包含药物样共晶配体的其他口袋的数量和邻居中的总口袋数量来计算的。令人惊讶的是,尽管 DLID 是在局部定义的,但可以通过对体积、埋置度和疏水性的对数进行简单线性回归来预测其全局趋势。为了将个体口袋的 DLID 与“靶标”联系起来,需要进行两级简化:选择每个蛋白质数据库(PDB)条目最佳的 DLID(因为给定的晶体结构可以有多个口袋),以及选择同一靶标所有 PDB 条目的中位数 DLID(因为同一蛋白质的不同晶体结构可能因伪影和真实构象变化而有所不同)。我们可以证明,在序列上可检测到同源的靶标之间的中位数 DLID 相当相似,并且中位数 DLID 与 Cheng 等人的“可成药性”估计相关(自然生物技术 2007,25,71-75)。

相似文献

1
Drug-like density: a method of quantifying the "bindability" of a protein target based on a very large set of pockets and drug-like ligands from the Protein Data Bank.类药性密度:一种基于蛋白质数据库中大量口袋和类药性配体来量化蛋白质靶标“可结合性”的方法。
J Chem Inf Model. 2010 Nov 22;50(11):2029-40. doi: 10.1021/ci100312t. Epub 2010 Oct 26.
2
Form follows function: shape analysis of protein cavities for receptor-based drug design.形式追随功能:用于基于受体的药物设计的蛋白质腔的形状分析。
Proteomics. 2009 Jan;9(2):451-9. doi: 10.1002/pmic.200800092.
3
Comprehensive identification of "druggable" protein ligand binding sites.“可成药”蛋白质配体结合位点的全面鉴定。
Genome Inform. 2004;15(2):31-41.
4
Structure-based druggability assessment--identifying suitable targets for small molecule therapeutics.基于结构的可药性评估——确定小分子治疗药物的合适靶点。
Curr Opin Chem Biol. 2011 Aug;15(4):463-8. doi: 10.1016/j.cbpa.2011.05.020. Epub 2011 Jun 23.
5
Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery.可成药性口袋和结合位点为中心的化学空间:药物发现的范式转变。
Drug Discov Today. 2010 Aug;15(15-16):656-67. doi: 10.1016/j.drudis.2010.05.015. Epub 2010 Jun 4.
6
Computational approaches to identifying and characterizing protein binding sites for ligand design.计算方法在识别和描述配体设计的蛋白质结合部位中的应用。
J Mol Recognit. 2010 Mar-Apr;23(2):209-19. doi: 10.1002/jmr.984.
7
Development of a rule-based method for the assessment of protein druggability.基于规则的蛋白质成药性评估方法的开发。
J Chem Inf Model. 2012 Apr 23;52(4):1027-38. doi: 10.1021/ci200613b. Epub 2012 Apr 9.
8
Understanding and predicting druggability. A high-throughput method for detection of drug binding sites.理解和预测药物可开发性。一种用于检测药物结合部位的高通量方法。
J Med Chem. 2010 Aug 12;53(15):5858-67. doi: 10.1021/jm100574m.
9
Pocket extraction on proteins via the Voronoi diagram of spheres.通过球体的Voronoi图对蛋白质进行口袋提取。
J Mol Graph Model. 2008 Apr;26(7):1104-12. doi: 10.1016/j.jmgm.2007.10.002. Epub 2007 Oct 7.
10
A large-scale computational approach to drug repositioning.一种用于药物重新定位的大规模计算方法。
Genome Inform. 2006;17(2):239-47.

引用本文的文献

1
A computational framework for identifying chemical compounds to bind Apolipoprotein E4 for Alzheimer's disease intervention.一种用于识别与载脂蛋白E4结合以干预阿尔茨海默病的化合物的计算框架。
Front Syst Biol. 2023 Jun 14;3:1188430. doi: 10.3389/fsysb.2023.1188430. eCollection 2023.
2
Ligand-binding pockets in RNA and where to find them.RNA中的配体结合口袋及其所在位置。
Proc Natl Acad Sci U S A. 2025 Apr 29;122(17):e2422346122. doi: 10.1073/pnas.2422346122. Epub 2025 Apr 22.
3
DRLiPS: a novel method for prediction of druggable RNA-small molecule binding pockets using machine learning.
DRLiPS:一种使用机器学习预测可成药RNA-小分子结合口袋的新方法。
Nucleic Acids Res. 2025 Mar 20;53(6). doi: 10.1093/nar/gkaf239.
4
Ligand-binding pockets in RNA, and where to find them.RNA中的配体结合口袋及其发现位置。
bioRxiv. 2025 Mar 15:2025.03.13.643147. doi: 10.1101/2025.03.13.643147.
5
Structural insights into human brachyury DNA recognition and discovery of progressible binders for cancer therapy.人类短尾相关蛋白DNA识别的结构见解及用于癌症治疗的可进展性结合剂的发现。
Nat Commun. 2025 Feb 14;16(1):1596. doi: 10.1038/s41467-025-56213-1.
6
Repurposing FDA-Approved Drugs Against Potential Drug Targets Involved in Brain Inflammation Contributing to Alzheimer's Disease.重新利用美国食品药品监督管理局(FDA)批准的药物,针对参与导致阿尔茨海默病的脑部炎症的潜在药物靶点。
Targets (Basel). 2024 Dec;2(4):446-469. doi: 10.3390/targets2040025. Epub 2024 Dec 4.
7
Enantioselective Protein Affinity Selection Mass Spectrometry (EAS-MS).对映体选择性蛋白质亲和选择质谱法(EAS-MS)
bioRxiv. 2025 Jan 22:2025.01.17.633682. doi: 10.1101/2025.01.17.633682.
8
Identifying Allosteric Small-Molecule Binding Sites of Inactive NS2B-NS3 Proteases of Pathogenic .鉴定致病性无活性NS2B-NS3蛋白酶的变构小分子结合位点
Viruses. 2024 Dec 24;17(1):6. doi: 10.3390/v17010006.
9
A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins.含WD40重复序列蛋白的靶标类配体可及性评估
J Med Chem. 2025 Jan 23;68(2):1092-1112. doi: 10.1021/acs.jmedchem.4c02010. Epub 2024 Nov 4.
10
Druggability Analysis of Protein Targets for Drug Discovery to Combat .用于药物研发以对抗……的蛋白质靶点成药潜力分析
Microorganisms. 2024 May 25;12(6):1073. doi: 10.3390/microorganisms12061073.